[go: up one dir, main page]

AR046603A1 - Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc - Google Patents

Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc

Info

Publication number
AR046603A1
AR046603A1 ARP040103867A ARP040103867A AR046603A1 AR 046603 A1 AR046603 A1 AR 046603A1 AR P040103867 A ARP040103867 A AR P040103867A AR P040103867 A ARP040103867 A AR P040103867A AR 046603 A1 AR046603 A1 AR 046603A1
Authority
AR
Argentina
Prior art keywords
cycloalkyl
nitrogen
sulfur
alkyl
oxygen
Prior art date
Application number
ARP040103867A
Other languages
English (en)
Inventor
Johnathan Laird Gross
Gary Paul Stack
Hong Gao
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR046603A1 publication Critical patent/AR046603A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92Naphthofurans; Hydrogenated naphthofurans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Se proporcionan compuestos o sales farmacéuticamente aceptables de los mismos: que son agonistas o agonistas parciales de los receptores del subtipo 2c de la serotonina cerebral. Los compuestos, y composiciones que contienen los compuestos, se pueden utilizar para tratar una variedad de trastornos del sistema nervioso central de tales como esquizofrenia. Reivindicación 1: Un compuesto de fórmula (1), o sales farmacéuticamente aceptables de los mismos; donde R y R' son, independientemente, hidrógeno, alquilo C1-6, cicloalquilo C3-6, o alquilcicloalquilo C4-12 que tienen de 3 a 6 carbonos en el anillo cicloalquilo; alternativamente R y R' se pueden tomar juntos con el nitrógeno al que están adheridos para formar un anillo C2-5, donde uno de los átomos de carbono del anillo está sustituido opcionalmente por nitrógeno, azufre u oxígeno; R1 y R2 son, cada uno, independientemente, hidrógeno, alquilo C1-6, cicloalquilo C3-6, o perfluoroalquilo C1-6; R3a y R3b son, independientemente, hidrógeno, halógeno, hidroxilo, alquilo C1-6, perfluoroalquilo C1-6, alcoxi C1-6, o perfluoroalcoxi C1-6; dos sustituyentes adyacentes seleccionados entre R4 y R5, o R5 y R6, o R6 y R7, junto con los átomos de carbono a los que están adheridos, forman una estructura cíclica seleccionada entre un cicloalquilo monocíclico C3-8, un cicloalquilo que forma un puente C5-10, un heterocicloalquilo de 3 a 8 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionadas independientemente entre nitrógeno, oxígeno, o azufre, arilo C5-10, o un heteroarilo de 5 a 10 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionadas independientemente entre nitrógeno, oxígeno, o azufre, donde la estructura monocíclica cicloalquilo o la estructura cíclica heterocicloalquilo pueden estar opcionalmente sustituidas en un único átomo de carbono con un cicloalquilo C3-5 o un heterocicloalquilo de 3 a 5 miembros que contienen 1 ó 2 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno, o azufre, para formar un grupo espirocíclico; los restantes sustituyentes R4 a R7 son, independientemente, hidrógeno, halógeno, ciano, hidroxilo, carboxilo, alquilo C1-8, perfluoroalquilo C1-6, alcoxi C1- 6, perfluoroalcoxi C1-6, arilo C5-10, ariloxi C5-10, heteroarilo de 5 a 10 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno o azufre, alquenilo C2-8, alcanoilo C2-6, alcanoiloxi C2-6, carboalcoxi C2-6, carboxamido, alcanamido C2-6, alcanosulfonamido C1-6, amino, monoalquilamino C1-6, dialquilamino C1-6 por una estructura alquilo, cicloalquilo C3-8, o heterocicloalquilo de 3 a 8 miembros que tienen de 1 a 3 heteroátomos cada uno seleccionados independientemente entre nitrógeno, oxígeno o azufre; y n es 1, 2 ó 3; donde cualquier grupo cicloalquilo o heterocicloalquilo está saturado o parcialmente saturado, y cualquier grupo arilo, heteroarilo, cicloalquilo, o heterocicloalquilo puede estar opcionalmente sustituido con 1 a 5 sustituyentes seleccionados independientemente entre halógeno, hidroxilo, alquilo C1-6, perfluoroalquilo C1-6, alcoxi C1-6, o perfluoroalcoxi C1-6.
ARP040103867A 2003-10-24 2004-10-25 Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc AR046603A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51426603P 2003-10-24 2003-10-24
US10/970,103 US7728155B2 (en) 2003-10-24 2004-10-21 Dihydrobenzofuranyl alkanamines and methods for using same as cns agents

Publications (1)

Publication Number Publication Date
AR046603A1 true AR046603A1 (es) 2005-12-14

Family

ID=34526975

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103867A AR046603A1 (es) 2003-10-24 2004-10-25 Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc

Country Status (10)

Country Link
US (1) US7728155B2 (es)
EP (1) EP1675842A1 (es)
JP (1) JP2007509167A (es)
AR (1) AR046603A1 (es)
AU (1) AU2004284072A1 (es)
BR (1) BRPI0415769A (es)
CA (1) CA2541472A1 (es)
MX (1) MXPA06004344A (es)
TW (1) TW200522942A (es)
WO (1) WO2005040146A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
CA2603900A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
BRPI0610037A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de dihidrobenzofurano e uso dos mesmos
GT200600159A (es) * 2005-04-22 2007-03-14 Derivados benzodioxano y benzodioxolano y usos de los mismos
MX2007012883A (es) 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
AU2006239922A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists
CA2605447A1 (en) * 2005-04-22 2006-11-02 Wyeth Therapeutic combinations for the treatment or prevention of psychotic disorders
TW200716584A (en) * 2005-04-22 2007-05-01 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
CN101203505A (zh) * 2005-04-22 2008-06-18 惠氏公司 苯并二氢吡喃和苯并吡喃衍生物及其用途
MX2007012882A (es) * 2005-04-22 2007-12-10 Wyeth Corp Nuevas combinaciones terapeuticas para el tratamiento o prevencion de la depresion.
EP1871354A1 (en) * 2005-04-22 2008-01-02 Wyeth Treatment of pain
US20060258712A1 (en) * 2005-04-24 2006-11-16 Wyeth Methods for modulating bladder function
AR060090A1 (es) * 2006-03-24 2008-05-21 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
US8158617B2 (en) 2006-05-16 2012-04-17 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND ITS USE
JP5526793B2 (ja) 2009-03-18 2014-06-18 Jnc株式会社 重合性液晶化合物、重合性液晶組成物およびその重合体
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
US20130267500A1 (en) 2010-09-01 2013-10-10 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2019131902A1 (ja) 2017-12-27 2019-07-04 武田薬品工業株式会社 腹圧性尿失禁および便失禁の治療薬

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1200892A (en) 1966-10-27 1970-08-05 Ward Blenkinsop & Co Ltd Production of 2-aminomethyl-2,3-dihydrobenzofurans
US3513239A (en) 1967-03-15 1970-05-19 Smithkline Corp Pharmaceutical compositions containing 2-aminoalkyl coumaran derivatives and methods of treating depression therewith
US3826835A (en) 1971-01-08 1974-07-30 Ciba Geigy Corp 8-benzofurylmethyl-1,3,8-triazaspiro(4,5)decanes as neuroleptics
JPS59186969A (ja) 1983-04-08 1984-10-23 Yoshitomi Pharmaceut Ind Ltd ベンゾフラン−およびベンゾピランカルボキサミド誘導体
US5008286A (en) * 1985-11-22 1991-04-16 Burroughs Wellcome Co. Certain substituted naphthofurans with anti-tumor properties
FR2601950B1 (fr) 1986-07-22 1988-11-10 Cerm Cent Europ Rech Mauvernay N,n-dimethyl-n'-benzoyl-n' ((2,3-dihydro) benzofuran-2-yl-methyl) 1,3-propanediamine, preparation et compositions pharmaceutiques les contenant
IT1239946B (it) 1990-03-12 1993-11-27 Biomedica Foscama Industria Chimicofarmaceutica Procedimento per la sintesi degli acidi 5-acilossi e 5-alcossi-2,3-diidro-4,6,7-trimetil-2-(rs)-benzofuranacetici
WO1991017144A1 (fr) 1990-05-02 1991-11-14 Yoshitomi Pharmaceutical Industries, Ltd. Compose amide, utilisation pharmaceutique de ce compose et nouvelles pyrrolidinemethyl-amines 1-substituee
JPH05194406A (ja) 1991-11-12 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 新規アミド化合物
JP3153335B2 (ja) 1992-06-05 2001-04-09 興和株式会社 キノリン誘導体又はその塩
FR2701479B1 (fr) 1993-02-11 1995-05-12 Pf Medicament Nouveaux dérivés hétérocycliques de l'aminométhyl-4 pipéridine, leur préparation et leur application en thérapeutique.
JPH06316563A (ja) 1993-05-06 1994-11-15 Yoshitomi Pharmaceut Ind Ltd アミド化合物
JP2999669B2 (ja) 1993-08-24 2000-01-17 株式会社三和化学研究所 ベンゾ[b]フランカルボキサミド誘導体、その製法及び用途
DE69524528T2 (de) 1994-10-14 2002-08-01 Merck Patent Gmbh ZNS wirksames (R)-(-)-2-[5-(4-Fluorophenyl)-3-pyridylmethylaminomethyl]chroman
WO1996030367A1 (en) 1995-03-27 1996-10-03 Hisamitsu Pharmaceutical Co., Inc. Piperidine derivatives
EP0846683B1 (en) 1996-12-03 2001-09-19 F. Hoffmann-La Roche Ag 4-Hydroxy-piperidine derivatives
JP2000007671A (ja) 1998-06-25 2000-01-11 Asahi Chem Ind Co Ltd 2,3−ジヒドロベンゾフラン誘導体
JP2000080091A (ja) 1998-06-26 2000-03-21 Asahi Chem Ind Co Ltd 2,3―ジヒドロベンゾフラン誘導体の製造方法
US6255324B1 (en) 1998-11-25 2001-07-03 Ned D. Heindel Amino-and mercurio-substituted 4′,5'-dihydropsoralens and therapeutical uses thereof
HK1042480A1 (zh) 1999-06-15 2002-08-16 Bristol-Myers Squibb Pharma Company 取代的稠杂环γ-咔啉
SE9902267D0 (sv) 1999-06-16 1999-06-16 Astra Ab New compounds
US6872718B1 (en) 1999-08-20 2005-03-29 Takeda Chemical Industries, Ltd. Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US7153852B2 (en) 2001-09-07 2006-12-26 Ono Pharmaceutical Co., Ltd. Indole compounds, process for producing the same and drugs containing the same as the active ingredient
US6569894B1 (en) 2001-10-04 2003-05-27 Bristol-Myers Squibb Company Arylalkylbenzofuran derivatives as melatonergic agents
EP1348708A1 (en) 2002-02-28 2003-10-01 Sanofi-Synthelabo Heteroaryl substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1H)one derivatives
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation

Also Published As

Publication number Publication date
CA2541472A1 (en) 2005-05-06
JP2007509167A (ja) 2007-04-12
US20050124692A1 (en) 2005-06-09
WO2005040146A1 (en) 2005-05-06
TW200522942A (en) 2005-07-16
BRPI0415769A (pt) 2006-12-26
MXPA06004344A (es) 2006-06-05
EP1675842A1 (en) 2006-07-05
US7728155B2 (en) 2010-06-01
AU2004284072A1 (en) 2005-05-06

Similar Documents

Publication Publication Date Title
AR046603A1 (es) Alcanaminas dihidrobenzofuranilo y metodos para su uso como farmacos en el snc
AR046309A1 (es) Derivados de dihidrobenzofuranilo alcanamina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos del sistema nervioso central.
AR050433A1 (es) Derivados piperidilo de quinazolina e isoquinolina
AR065718A1 (es) Compuestos heterociclicos nitrogenados,utiles en el diagnostico y tratamiento de trastornos hiperproliferativos.
AR061564A1 (es) Derivados de isoindoles, composiciones farmaceuticas y usos
AR054035A1 (es) Derivados benzodioxano y benzodioxolano y uso de los mismos
CO5570676A2 (es) Nuevos compuestos de alquilo con efecto antagonico de la hcm y medicamentos que contienen estos compuestos
AR078756A1 (es) Moduladores alostericos positivos (map)
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
AR060593A1 (es) 5-amido-2-carboxiamida-indoles
AR074358A1 (es) Derivados de pirazina como inhibidores de la fosfodiesterasa 10
AR047682A1 (es) Derivados tetrahidroisoquinolinilo de quinazolina e isoquinolina
AR056320A1 (es) Derivados de cromano y cromeno, procesos de obtencion, composiciones farmaceuticas y usos de los mismos
AR056879A1 (es) Antagonistas del receptor 3 de la histamina
ES2179490T3 (es) Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
AR096640A1 (es) Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AR037489A1 (es) Quinolinas sustituidas y proceso para su preparacion
AR043180A1 (es) Derivados de heterociclil-3-sulfonilazaindol o -azaindazol como ligandos de 5-hidroxitriptamina-6
AR051090A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
PE20081844A1 (es) DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a
CR9959A (es) Derivados de pirazol
AR059686A1 (es) Piperazinas terapeuticas
AR059428A1 (es) Pirazoles para el tratamiento de enfermedades mediadas por la modulacion de los receptores de histamina h3 y una composicion farmaceutica que los comprende.
AR118082A1 (es) Inhibidores de enzimas

Legal Events

Date Code Title Description
FB Suspension of granting procedure